Collegium Pharmaceutical, Inc. (COLL)

Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $2.04 per share, missing the Zacks Consensus Estimate of $2.19 per share. This compares to earnings of $1.77 per share a year ago.

– Generated Quarterly Net Revenues of $205.4 Million, Up 13% Year-over-Year, and Record Full-Year Net Revenues of $780.6 Million, Up 24% Year-over-Year –

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Collegium Pharmaceutical, Inc. (NASDAQ: COLL - Get Free Report) crossed below its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $47.17 and traded as low as $45.53. Collegium Pharmaceutical shares last traded at $46.10, with a volume of 212,736 shares changing hands. Analyst Ratings Changes A

Collegium Pharmaceutical (NASDAQ: COLL - Get Free Report) and Pivotal Therapeutics (OTCMKTS:PVTTF - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends. Risk and Volatility Collegium Pharmaceutical has a beta

Emerald Advisers LLC reduced its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL) by 23.6% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 639,694 shares of the specialty pharmaceutical company's stock after selling 197,855 shares during the

Collegium Pharmaceutical demonstrates strong profitability, upgraded 2026 guidance, and a robust balance sheet, reinforcing my bullish outlook and conviction upgrade. COLL's growth is shifting from Xtampza ER to Jornay PM, which is expected to drive $190M–$200M in 2025 revenue and deeper ADHD market penetration. The pain portfolio remains a stable cash generator, with authorized generics providing a smart revenue stream and mitigating immediate generic erosion risks.

SG Americas Securities LLC grew its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL) by 215.6% during the third quarter, according to its most recent filing with the SEC. The firm owned 28,978 shares of the specialty pharmaceutical company's stock after acquiring an additional 19,796 shares during the period. SG Americas Securities

STOUGHTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have four poster presentations highlighting real-world data from its ADHD product, Jornay PM (methylphenidate HCl), a central nervous system (CNS) stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in people 6 years of age and older and developed using a novel delayed-release extended-release delivery platform, at the American Professional Society of ADHD and Related Disorders (APSARD) Annual Conference being held from January 15-18, 2026, in San Diego, California.

On Dec. 8, 2025, the Executive Vice President and Chief Commercial Officer of Collegium Pharmaceutical sold 17,600 shares directly through an exercise of options. The sale represented 14.5% of Dreyer's direct holdings at the time, reducing his direct ownership to 103,613 shares.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

– Product Revenues, Net Expected in the Range of $805 Million to $825 Million – – Jornay PM ® Net Revenue Expected in the Range of $190 Million to $200 Million – – Adjusted EBITDA* Expected in the Range of $455 Million to $475 Million – STOUGHTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced its 2026 full-year financial guidance and provided a business update.

STOUGHTON, Mass., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced the closing of its inaugural syndicated credit facility.

Shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL - Get Free Report) reached a new 52-week high on Friday. The stock traded as high as $50.00 and last traded at $49.9750, with a volume of 203913 shares. The stock had previously closed at $49.58. Analyst Ratings Changes Several research firms have commented on COLL. Barclays initiated

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.